{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:47:43Z","timestamp":1785412063381,"version":"3.56.0"},"reference-count":22,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Dolutegravir (DTG) became central to South Africa\u2019s (SA\u2019s) first-line human immunodeficiency virus (HIV) regimen since 2019, offering improved tolerability, fewer drug\u2013drug interactions, and a higher resistance barrier compared to efavirenz (EFV). Concerns remain about the long-term cardiovascular, metabolic, and renal consequences of DTG-based therapy in people living with HIV (PLHIV). This study compared demographic and clinical outcomes across three groups: (1) those on tenofovir, emtricitabine and efavirenz (TEE); (2) those on tenofovir, lamivudine and dolutegravir (TLD); and (3) those switched from TEE to TLD.\nMethods:\u00a0This retrospective, analytical study was conducted at an urban district hospital in KwaZulu-Natal. A sample of 212 patients was calculated using a chi-squared test for multiple proportions (80% power, 95% confidence interval). Data extracted at baseline, 6 and 12 months, were analysed with SPSS version 28.0.\nResults:\u00a0There were statistically significant differences between the three groups. The Switch group showed a higher incidence of new hypertension (HT) (9.9%,\u00a0p\u00a0= 0.03) and chronic kidney disease (CKD) (12.1%,\u00a0p\u00a0= 0.01). TLD group maintained stable outcomes. TEE group had the highest incidence of newly diagnosed dyslipidaemia.\nConclusion:\u00a0DTG-based therapy remains the preferred regimen in SA, its long-term metabolic and renal impact in patients switching from EFV warrants careful surveillance. The increased rates of HT and CKD in the Switch Group emphasises the need for closer monitoring to mitigate against complications.\nContribution:\u00a0This research contributes to the body of evidence on DTG, highlighting its benefits and the clinical challenges of managing ageing PLHIV with multimorbidity.<\/jats:p>","DOI":"10.4102\/safp.v67i1.6171","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:29:57Z","timestamp":1762763397000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients"],"prefix":"10.4102","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4689-5200","authenticated-orcid":false,"given":"Shira","family":"Kimberley","sequence":"first","affiliation":[{"name":"Department of Haematology, Faculty of Health, Victoria Mxenge Hospital, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-1168","authenticated-orcid":false,"given":"Mergan","family":"Naidoo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qzfn040","id-type":"ROR","asserted-by":"publisher"}],"name":"University of KwaZulu-Natal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"ref0","unstructured":"Republic of South Africa, National Department of Health, Republic of South Africa. ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. Pretoria: National Department of Health, Republic of South Africa; 2023."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sebilo M, Ledibane NRT, Takuva S. Incidence of cardiometabolic diseases in a Lesotho HIV cohort: Evidence for policy decision-making. South Afr J HIV Med. 2021;22(1): 1246. https:\/\/doi.org\/10.4102\/sajhivmed.v22i1.1246","DOI":"10.4102\/sajhivmed.v22i1.1246"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int Med Case Rep J. 2021;14:503\u2013507. https:\/\/doi.org\/10.2147\/IMCRJ.S323233","DOI":"10.2147\/IMCRJ.S323233"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211\u2013219. https:\/\/doi.org\/10.1007\/s40261-014-0266-2","DOI":"10.1007\/s40261-014-0266-2"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sinxadi PZ, McIlleron HM, Dave JA, et al. Plasma efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (Baltimore). 2016;95(2):e2385. https:\/\/doi.org\/10.1097\/MD.0000000000002385","DOI":"10.1097\/MD.0000000000002385"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Eyawo O, Brockman G, Goldsmith CH, et al. Risk of myocardial infarction among people living with HIV: An updated systematic review and meta-analysis. BMJ Open. 2019;9(9):e025874. https:\/\/doi.org\/10.1136\/bmjopen-2018-025874","DOI":"10.1136\/bmjopen-2018-025874"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: Meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13(2):102\u2013111. https:\/\/doi.org\/10.1097\/COH.0000000000000445","DOI":"10.1097\/COH.0000000000000445"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Rebeiro PF, Emond B, Rossi C, et al. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: A retrospective analysis of insurance claims in the United States. J Int AIDS Soc. 2023;26(6):e26123. https:\/\/doi.org\/10.1002\/jia2.26123","DOI":"10.1002\/jia2.26123"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Norwood J, Turner M, Bofill C, et al. Brief report: Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527\u2013531. https:\/\/doi.org\/10.1097\/QAI.0000000000001525","DOI":"10.1097\/QAI.0000000000001525"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Griesel R, Maartens G, Chirehwa M, et al. CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz. Clin Infect Dis. 2021;73(11):e3902\u2013e3909. https:\/\/doi.org\/10.1093\/cid\/ciab804","DOI":"10.1093\/cid\/ciaa1073"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990\u2013996. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04440.x","DOI":"10.1111\/j.1365-2125.2012.04440.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70(1):29\u201335. https:\/\/doi.org\/10.1007\/s00228-013-1590-9","DOI":"10.1007\/s00228-013-1590-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lu L, Li X, Liu X, et al. Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on dolutegravir-containing therapy. Infect Drug Resist. 2022;15:1695\u20131706. https:\/\/doi.org\/10.2147\/IDR.S347054","DOI":"10.2147\/IDR.S347054"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Barata R, Marques da Costa B, Navarro D, et al. Acute interstitial nephritis due to dolutegravir: The first case reported. Nefrologia (Engl Ed). 2023;43(3):370\u2013373. https:\/\/doi.org\/10.1016\/j.nefroe.2022.11.012","DOI":"10.1016\/j.nefro.2021.07.015"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Serra A, De Lazzari E, Berrocal L, et al. Clinical use and effectiveness of dolutegravir and lamivudine: A long-term, real-world, retrospective study. J Antimicrob Chemother. 2023;78(8):1955\u20131962. https:\/\/doi.org\/10.1093\/jac\/dkad189","DOI":"10.1093\/jac\/dkad189"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gebremedhin T, Aynalem M, Adem M, Geremew D, Aleka Y, Kiflie A. Dolutegravir based therapy showed CD4+T cell count recovery and viral load suppression among ART na\u00efve people living with HIV AIDS: A pilot evaluation. Sci Rep. 2024;14(1): 3297. https:\/\/doi.org\/10.1038\/s41598-024-53282-y","DOI":"10.1038\/s41598-024-53282-y"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zhong M, Li M, Qi M, et al. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-na\u00efve patients with advanced HIV infection in Nanjing, China. Front Immunol. 2023;13:1033098. https:\/\/doi.org\/10.3389\/fimmu.2022.1033098","DOI":"10.3389\/fimmu.2022.1033098"},{"key":"ref17","unstructured":"National Department of Health, Republic of South Africa. Standard Treatment Guidelines and Essential Medicines List for South Africa: Primary Healthcare Level, 2023 Edition. Pretoria: National Department of Health; 2023."},{"key":"ref18","unstructured":"National Department of Health, Republic of South Africa. Standard Treatment Guidelines and Essential Medicines List for South Africa: Primary Healthcare Level. 7th ed. Pretoria: National Department of Health; 2020."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Romo ML, Patel RC, Edwards JK, et al. Disparities in dolutegravir uptake affecting females of reproductive age with HIV in low- and middle-income countries after initial concerns about teratogenicity: An observational study. Ann Intern Med. 2022;175(1):84\u201394. https:\/\/doi.org\/10.7326\/M21-3037","DOI":"10.7326\/M21-3037"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mbabazi L, Nabaggala MS, Kiwanuka S, et al. Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda. BMC Womens Health. 2022;22(1):262. https:\/\/doi.org\/10.1186\/s12905-022-01842-7","DOI":"10.1186\/s12905-022-01842-7"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Summers NA, Lahiri CD, Angert CD, et al. Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. J Acquir Immune Defic Syndr. 2020;85(3):355\u2013362. https:\/\/doi.org10.1097\/QAI.0000000000002447","DOI":"10.1097\/QAI.0000000000002447"}],"container-title":["South African Family Practice"],"original-title":[],"link":[{"URL":"https:\/\/safpj.co.za\/index.php\/safpj\/article\/view\/6171\/9907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:30:01Z","timestamp":1762763401000},"score":1,"resource":{"primary":{"URL":"https:\/\/safpj.co.za\/index.php\/safpj\/article\/view\/6171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.4102\/safp.v67i1.6171","relation":{},"ISSN":["2078-6190","2078-6204"],"issn-type":[{"value":"2078-6190","type":"print"},{"value":"2078-6204","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"a6171"}}